Search results for " liver disease"

showing 10 items of 559 documents

Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification.

2018

Background & Aims: Controlled attenuation parameter (CAP) is a novel non-invasive measure of hepatic steatosis, but it has not been evaluated in alcoholic liver disease. Therefore, we aimed to validate CAP for the assessment of biopsy-verified alcoholic steatosis and to study the effect of alcohol detoxification on CAP. Methods: This was a cross-sectional biopsy-controlled diagnostic study in four European liver centres. Consecutive alcohol-overusing patients underwent concomitant CAP, regular ultrasound, and liver biopsy. In addition, we measured CAP before and after admission for detoxification in a separate single-centre cohort. Results: A total of 562 patients were included in the s…

MaleAlcoholic liver diseasemedicine.medical_treatmentBiopsyGastroenterologyCohort StudiesSensitivity0302 clinical medicineInterquartile rangeRisk FactorsAlcohol detoxificationNon-invasiveSteatohepatitisUltrasonography2. Zero hungerMetabolic Syndromemedicine.diagnostic_testAlcohol AbstinenceFatty liverAlcohol detoxificationDiagnostic testMiddle Aged3. Good healthAlcoholismLiver030220 oncology & carcinogenesisLiver biopsyControlled attenuation parameterSpecificityElasticity Imaging Techniques030211 gastroenterology & hepatologyFemaleFatty Liver AlcoholicAdultmedicine.medical_specialty03 medical and health sciencesPredictive Value of TestsFatty liverInternal medicinemedicineHumansFibroScanHepatologybusiness.industryAlcoholic liver diseasemedicine.diseaseCross-Sectional StudiesConcomitantSteatohepatitisSteatosisbusinessJournal of hepatology
researchProduct

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 tria…

2019

© 2019 Elsevier Ltd. All rights reserved.

MaleBiopsyClinical Trial Phase IIIAdministration Oral030204 cardiovascular system & hematologyChronic liver diseaseSettore MED/04Biomarkers/analysisGastroenterologychemistry.chemical_compound0302 clinical medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D013485Liver Function TestsNon-alcoholic Fatty Liver DiseaseClinical endpointMedicine030212 general & internal medicine610 Medicine & healthChenodeoxycholic Acid/administration & dosageeducation.field_of_studyLiver Function TestResearch Support Non-U.S. Gov'tFatty liverObeticholic acidNASH OBETICHOLIC ACIDGeneral Medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D052061Middle AgedMulticenter Study/dk/atira/pure/researchoutput/pubmedpublicationtype/D016448Randomized Controlled TrialAdministrationFemale/dk/atira/pure/researchoutput/pubmedpublicationtype/D016449Administration Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver DiseaseHumanOralmedicine.medical_specialtyPopulationPlaceboChenodeoxycholic Acid03 medical and health sciencesResearch Support N.I.H. ExtramuralDouble-Blind MethodInternal medicineJournal ArticleHumans/dk/atira/pure/researchoutput/pubmedpublicationtype/D017428educationIntention-to-treat analysisbusiness.industryBiomarkerInterim analysismedicine.diseaseNon-alcoholic Fatty Liver Disease/drug therapychemistryHuman medicine/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428businessBiomarkersAdministration; Oral; Biomarkers; Biopsy; Chenodeoxycholic Acid; Double-Blind Method; Female; Humans; Liver Function Tests; Male; Middle Aged; Non-alcoholic Fatty Liver Disease
researchProduct

Oxidative and Nitrosative Pattern in Circulating Leukocytes of Very Early/Early Hepatocellular Carcinoma Patients

2020

Background/aim In chronic liver disease, various immune cell subsets exert pro or anti-tumour effects by releasing reactive oxygen and nitrogen species (ROS, RNS). Here, we evaluated the oxidative and nitrosative pattern in peripheral blood leukocyte subpopulations of early hepatocellular carcinoma (HCC) patients compared with HCC-free cirrhotic patients. Materials and methods Venous blood samples from 18 HCC-free cirrhotic patients and 17 early stage HCC patients were collected to determine ROS, RNS and reduced glutathione levels in isolated leukocytes analyzed by flow cytometry. Results Intracellular levels of ROS and glutathione were higher in lymphocytes, monocytes, and neutrophils from…

MaleCancer ResearchCarcinoma HepatocellularCirrhosisChronic liver diseasemedicine.disease_causeNitric oxide03 medical and health scienceschemistry.chemical_compound0302 clinical medicineImmune systemRisk FactorsSuperoxidesLeukocytesmedicineHumansEarly Hepatocellular CarcinomaAgedNeoplasm StagingAged 80 and overbusiness.industryLiver NeoplasmsGeneral MedicineGlutathioneMiddle AgedFlow CytometryNeoplastic Cells Circulatingmedicine.diseaseReactive Nitrogen Speciesdigestive system diseasesOxidative StressOncologychemistry030220 oncology & carcinogenesisImmunologyFemaleReactive Oxygen SpeciesbusinessOxidation-ReductionOxidative stressIntracellularAnticancer Research
researchProduct

Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease

2017

Abstract In an increasing proportion of cases, hepatocellular carcinoma (HCC) develops in patients with nonalcoholic fatty liver disease (NAFLD). Mutations in telomerase reverse transcriptase (hTERT) are associated with familial liver diseases. The aim of this study was to examine telomere length and germline hTERT mutations as associated with NAFLD‐HCC. In 40 patients with NAFLD‐HCC, 45 with NAFLD‐cirrhosis and 64 healthy controls, peripheral blood telomere length was evaluated by qRT‐PCR and hTERT coding regions and intron–exon boundaries sequenced. We further analyzed 78 patients affected by primary liver cancer (NAFLD‐PLC, 76 with HCC). Enrichment of rare coding mutations (allelic frequ…

MaleCancer ResearchHepatocellular carcinomaSeverity of Illness IndexGermlineLoss of heterozygosityCohort StudiesLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseNuclear Medicine and ImagingNonalcoholic fatty liver disease80 and overLeukocytesTelomeraseTelomere ShorteningOriginal ResearchCancer BiologyAged 80 and overHepatocellular carcinoma; Nonalcoholic fatty liver; Rare germline mutations; Telomerase reverse transcriptase; Telomere; Oncology; Radiology Nuclear Medicine and Imaging; Cancer ResearchtelomereLiver Neoplasmstelomerase reverse transcriptaseMiddle Aged3. Good healthPhenotypeOncology030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleDisease SusceptibilityRadiologySequence AnalysisRare germline mutationCarcinoma HepatocellularMononuclearBiology03 medical and health sciencesGermline mutationHepatocellular carcinoma; Nonalcoholic fatty liver; Rare germline mutations; Telomerase reverse transcriptase; Telomere; Aged; Aged 80 and over; Alleles; Amino Acid Substitution; Carcinoma Hepatocellular; Cohort Studies; Computational Biology; Disease Susceptibility; Female; Genetic Association Studies; Humans; Leukocytes Mononuclear; Liver Neoplasms; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phenotype; Sequence Analysis DNA; Severity of Illness Index; Telomerase; Telomere; Telomere Shortening; Germ-Line Mutationmedicinenonalcoholic fatty liverHumansRadiology Nuclear Medicine and imagingTelomerase reverse transcriptaseAllelesGenetic Association StudiesGerm-Line MutationAgedrare germline mutationsCarcinomaComputational BiologyHepatocellularDNASequence Analysis DNAmedicine.diseasedigestive system diseasesTelomereAmino Acid SubstitutionCancer researchLeukocytes MononuclearCancer Medicine
researchProduct

Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

2022

Background: Comprehensive and contemporary data pertaining large populations of patients with Primary Biliary Cholangitis (PBC) and hepatocellular carcinoma (HCC) are missing. Aim: To describe main characteristics and outcome of PBC patients with HCC diagnosed in the new millennium. Methods: Analysing the Italian Liver Cancer registry we identified 80 PBC patients with HCC diagnosed after the year 2000, and described their clinical characteristics, access to treatment and survival. Results: Median age of patients was 71 years and 50.0% were males. Cirrhosis was present in 86.3% of patients, being well-compensated in 58.0%. Median HCC diameter was smaller in patients under surveillance (2.6 …

MaleCarcinoma HepatocellularCholestatic liver disease; Outcome; Surveillance; Survival; TreatmentSurveillanceHepatologySurvivalPrognosiLiver Cirrhosis BiliaryRisk FactorSettore MED/12 - GASTROENTEROLOGIALiver NeoplasmsGastroenterologyCholestatic liver diseasePrognosisTreatmentRisk FactorsHumansFemaleTreatment.HumanAgedOutcome
researchProduct

Epidemiological and clinical scenario of chronic liver diseases in Italy: Data from a multicenter nationwide survey

2016

The last Italian prevalence survey on chronic liver diseases (CLD) was performed in 2001. The present study evaluated the changes occurring over thirteen years. Background The last Italian prevalence survey on chronic liver diseases (CLD) was performed in 2001. The present study evaluated the changes occurring over thirteen years. Methods We enrolled 2,557 CLD consecutive patients in 16 Italian liver units in 2014. Results HBV etiology accounted for 513 (20.2%) cases, alone in 439 and associated with HCV and/or alcohol abuse in 74. Of these 513, 11.9% were anti-HDV-positive and 7.2% HBeAg-positive. HCV alone was responsible for 50.3% of CLD and with alcohol abuse for 5.9%. HCV RNA was detec…

MaleCirrhosisAlcohol abuseGastroenterology0302 clinical medicineNon-alcoholic Fatty Liver DiseaseSurveys and QuestionnairesEpidemiologyOutpatients80 and overSurveys and QuestionnaireChronic hepatitis; Chronic liver diseases; HCC; Liver cirrhosis; Adolescent; Adult; Aged; Aged 80 and over; Alcoholism; Carcinoma Hepatocellular; Female; Genotype; Hepatitis B; Hepatitis C; Humans; Inpatients; Italy; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Outpatients; Surveys and Questionnaires; Young Adult; Hepatology; Gastroenterology030212 general & internal medicineYoung adultHCCChronic liver diseasesChronic hepatitisAged 80 and overMedicine (all)Liver NeoplasmsChronic liver diseaseGastroenterologyvirus diseasesOutpatientHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis CAlcoholismItalyLiver Neoplasm030211 gastroenterology & hepatologyFemaleInpatientHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularAdolescentGenotypeLiver CirrhosiChronic hepatitis; Chronic liver diseases; HCC; Liver cirrhosis; Medicine (all); Hepatology; Gastroenterology03 medical and health sciencesYoung AdultInternal medicinemedicineHumansAgedInpatientsHepatologybusiness.industryCarcinomaHepatocellularHepatologymedicine.diseasedigestive system diseasesLiver cirrhosisEtiologyChronic hepatitibusiness
researchProduct

Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study.

2012

International audience; PURPOSE: To compare pure molecular diffusion, D, perfusion-related diffusion, D*, and perfusion fraction, f, determined from diffusion-weighted (DW) magnetic resonance (MR) imaging on the basis of the intravoxel incoherent motion (IVIM) theory in patients with type 2 diabetes with and without liver steatosis. MATERIALS AND METHODS: This prospective study was approved by the appropriate ethics committee, and written informed consent was obtained from all patients. Between December 2009 and September 2011, 108 patients with type 2 diabetes (51 men, 57 women; mean age, 50 years) underwent 3.0-T single-voxel point-resolved proton MR spectroscopy of the liver (segment VII…

MaleCirrhosisMagnetic Resonance SpectroscopyMESH : Fatty Liver[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/ImagingMESH : AgedMESH : Prospective Studies030218 nuclear medicine & medical imagingMESH: Linear Models0302 clinical medicineNuclear magnetic resonanceMESH: Aged 80 and overMESH : Diabetes Mellitus Type 2Non-alcoholic Fatty Liver DiseaseMESH : Linear ModelsNonalcoholic fatty liver diseaseMESH : FemaleProspective StudiesMESH: Fatty LiverIntravoxel incoherent motion[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingAged 80 and overMESH: AgedMESH: Statistics NonparametricMESH: Middle Aged[ INFO.INFO-IM ] Computer Science [cs]/Medical ImagingFatty liverMiddle AgedMESH : AdultMESH : Diffusion Magnetic Resonance Imaging3. Good health030220 oncology & carcinogenesisPotential confounderFemaleRadiologyMESH: Diabetes Mellitus Type 2Adultmedicine.medical_specialtyMESH : MaleMESH: Diffusion Magnetic Resonance ImagingStatistics Nonparametric03 medical and health sciencesmedicine[INFO.INFO-IM]Computer Science [cs]/Medical ImagingHumansRadiology Nuclear Medicine and imagingMESH : Middle AgedMESH : Aged 80 and overMESH : Statistics NonparametricAgedMESH: Humansbusiness.industryMESH: Magnetic Resonance SpectroscopyMESH : HumansMESH: Biological MarkersMESH: Adultmedicine.diseaseMr imagingMESH: MaleMESH: Prospective StudiesFatty LiverMESH : Biological MarkersDiffusion Magnetic Resonance ImagingDiabetes Mellitus Type 2Linear ModelsMESH : Magnetic Resonance SpectroscopySteatosisbusinessMESH: FemaleBiomarkersDiffusion MRI
researchProduct

Characteristics of patients with hepatitis C virus-related chronic liver diseases just before the era of oral direct-acting antiviral therapy in Italy

2018

Background In 2017, oral direct-acting antiviral (DAA) therapy for chronic hepatitis C virus (HCV) infection became available free of charge for all HCV-RNA-positive patients, irrespective of their fibrosis stage. Aim The aim of this study was to evaluate the characteristics of HCV-related chronic liver disease (CLD) in Italy just before the introduction of DAA therapy. Patients and methods Patients with CLD were enrolled in two national surveys conducted in 2001 and in 2014. The two surveys prospectively enrolled patients aged older than 18 years referring to Italian liver units throughout the country using a similar clinical approach and analytical methods. Results Out of the 12 564 patie…

MaleCirrhosisTime FactorsAdministration OralHepacivirusmedicine.disease_causeChronic liver diseaseSeverity of Illness Index0302 clinical medicineRisk FactorsOdds RatioPrevalenceMedicine030212 general & internal medicineProspective StudiesMultivariate AnalysiGastroenterologyHealth SurveyMiddle AgedViral LoadItalyRNA Viral030211 gastroenterology & hepatologyFemaleHumanAdultmedicine.medical_specialtyLogistic ModelTime FactorGenotypeHepatitis C virusAntiviral AgentsVirus03 medical and health sciencesAge DistributionInternal medicinechronic hepatitis CHumansSex DistributionProtective FactorAgedAntiviral AgentCross-Sectional StudieHepatitis B virusHepaciviruChi-Square DistributionHepatologybusiness.industryRisk Factorchronic liver diseaseBiomarkerOdds ratioHepatitis C AntibodiesHepatitis C ChronicProtective Factorsmedicine.diseaseHealth SurveysConfidence intervaldirect-acting antiviral therapyProspective Studiehepatitis infectionCross-Sectional StudiesLogistic ModelsMultivariate AnalysisEtiologyHepatitis C AntibodiebusinessBiomarkers
researchProduct

Hepatoprotective and anti-inflammatory effects of total flavonoids of Qu Zhi Ke (peel of Citrus changshan-huyou) on non-alcoholic fatty liver disease…

2019

Abstract Background Citrus flavonoids, consisting of naringin, narirutin, neohesperidine, etc., have therapeutic activities for the treatment of lipometabolic disorders. The peel of Citrus changshan-huyou (Qu Zhi Ke, QZK) is a new source of flavonoids, but attracted little attention so far. Hypothesis QZK should possess therapeutic effects against lipometabolic disorders due to the flavonoids it contains. Study design In this study, we extracted and purified the flavonoids of QZK (TFCH) and established an obesity-induced non-alcoholic fatty liver disease (NAFLD) model of rats. TFCH was given orally for 8 weeks, and its anti-NAFLD effects and potential mechanism were evaluated. Methods The f…

MaleCitrusmedicine.drug_classFlavonoidPharmaceutical SciencePharmacologyDiet High-FatProtective AgentsAnti-inflammatoryProinflammatory cytokineRats Sprague-Dawley03 medical and health scienceschemistry.chemical_compound0302 clinical medicineWestern blotNon-alcoholic Fatty Liver DiseaseDrug DiscoveryNonalcoholic fatty liver diseasemedicineAnimalsPhosphorylationNaringin030304 developmental biologyFlavonoidsPharmacologychemistry.chemical_classification0303 health sciencesNarirutinmedicine.diagnostic_testPlant ExtractsAnti-Inflammatory Agents Non-SteroidalFatty liverNF-kappa Bfood and beveragesmedicine.diseaseGene Expression RegulationLiverComplementary and alternative medicinechemistry030220 oncology & carcinogenesisMolecular MedicineMitogen-Activated Protein KinasesPhytomedicine
researchProduct

Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: An 8-month prospective pi…

2015

Objective: To explore the effects of the glucagon-like peptide-1 receptor analogue liraglutide on subclinical atherosclerosis in diabetic subjects with non-alcoholic fatty liver disease (NAFLD).Research design and methods: In this 8-month prospective study, 29 subjects with type 2 diabetes (T2DM) and NAFLD (16 men and 13 women, mean age: 61 ± 10 years) were matched for age and gender with 29 subjects with T2DM without NAFLD (16 men and 13 women, mean age: 61 ± 8 years). Liraglutide 0.6 mg/day for 2 weeks, followed by 1.2 mg/day, was given in addition to metformin.Main outcome measures: Anthropometric variables, glucometabolic parameters and carotid intima-media thickness (IMT) using B-mode …

MaleClinical BiochemistryPilot ProjectsType 2 diabetesCarotid Intima-Media ThicknessGastroenterologychemistry.chemical_compoundRisk FactorsDrug DiscoveryProspective StudiesProspective cohort studyliraglutideMedicine (all)Fatty liverLipidMiddle AgedLipidsHemoglobin AAtherosclerosiFemalemedicine.drugHumanmedicine.medical_specialtycarotid intima-media thickneInternal medicineDiabetes mellitusmedicineHumansHypoglycemic AgentsPilot ProjectAgedGlycated HemoglobinHemoglobin A GlycosylatedPharmacologytype 2 diabeteHypoglycemic AgentLiraglutidebusiness.industryRisk FactorDrug Discovery3003 Pharmaceutical Sciencenutritional and metabolic diseasesnon-alcoholic fatty liver diseaseAtherosclerosismedicine.diseaseProspective StudieEndocrinologychemistryIntima-media thicknessDiabetes Mellitus Type 2Glycated hemoglobinbusiness
researchProduct